364 related articles for article (PubMed ID: 30536446)
1. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
Chukir T; Liu Y; Farooki A
Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A; Xourafa A; Rapisarda R; Castellino P
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
4. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M
Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145
[TBL] [Abstract][Full Text] [Related]
5. Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
Abdel-Rahman O
Expert Rev Anticancer Ther; 2016 Aug; 16(8):885-91. PubMed ID: 27210216
[TBL] [Abstract][Full Text] [Related]
6. The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.
Candelaria-Quintana D; Dayao ZR; Royce ME
Breast Cancer Res Treat; 2012 Apr; 132(2):355-63. PubMed ID: 21987034
[TBL] [Abstract][Full Text] [Related]
7. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
8. Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.
Tremblay D; Patel V; Fifer KM; Caro J; Kolodka O; Mandelli J; Shapiro CL
Support Care Cancer; 2018 Jan; 26(1):197-202. PubMed ID: 28744736
[TBL] [Abstract][Full Text] [Related]
9. Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors.
Rachner TD; Göbel A; Jaschke NP; Hofbauer LC
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32674135
[TBL] [Abstract][Full Text] [Related]
10. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
[TBL] [Abstract][Full Text] [Related]
12. Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.
Bassatne A; Bou Khalil A; Chakhtoura M; Arabi A; Van Poznak C; El-Hajj Fuleihan G
Metabolism; 2022 Mar; 128():154962. PubMed ID: 34958816
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefits of bone targeted agents in early breast cancer.
Coleman R
Breast; 2019 Nov; 48 Suppl 1():S92-S96. PubMed ID: 31839171
[TBL] [Abstract][Full Text] [Related]
14. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Gonzalez-Rodriguez E; Aubry-Rozier B; Stoll D; Zaman K; Lamy O
Breast Cancer Res Treat; 2020 Jan; 179(1):153-159. PubMed ID: 31598815
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic approaches for protecting bone health in patients with breast cancer.
Lüftner D; Niepel D; Steger GG
Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
[TBL] [Abstract][Full Text] [Related]
16. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
[TBL] [Abstract][Full Text] [Related]
17. Managing Bone Health in Breast Cancer.
Kearns AE
Endocr Pract; 2023 May; 29(5):408-413. PubMed ID: 36509360
[TBL] [Abstract][Full Text] [Related]
18. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
Popp AW; Zysset PK; Lippuner K
Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
[TBL] [Abstract][Full Text] [Related]
19. Denosumab: A Review in Postmenopausal Osteoporosis.
Deeks ED
Drugs Aging; 2018 Feb; 35(2):163-173. PubMed ID: 29435849
[TBL] [Abstract][Full Text] [Related]
20. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
